CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

November 13, 2025

To The Manager, Listing Department **National Stock Exchange of India Ltd**. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department **BSE Limited** Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960

Dear Sir/Ma'am,

Sub.: Investor's Presentation for the Second Quarter and half year ended September 30, 2025

Pursuant to Regulation 30 of Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015," INVESTOR'S PRESENTATION" on Financial Results for the Second Quarter and half year ended September 30, 2025 is enclosed.

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Hina Ronak Patel
Digitally signed by Hina Ronak Patel
Date: 2025.11.13 22:27:19 +05'30'

Ms. Hina Patel
Company Secretary and Compliance Officer
(ACS:56541)

Encl: As above

CONCORD BIOTECH

Concord Biotech Limited

Investor Presentation – November 2025

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Concord Biotech Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

Q2 & H1FY26 Key Financial Highlights

Q2 & H1FY26 Key Highlights

Regulatory Approvals for multiple sites ensuring business continuity and greater global market penetration

Inspection by United States Food and Drug Administration (US FDA)

- Company has received an Establishment Inspection Report (EIR) from the US FDA for inspection at facility at Dholka. This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.

Inspection by European Union Good Manufacturing Practices (EU GMP)

- Successful completion of EU GMP inspection at our facility at Dholka. It reflects our dedication to excellence and our continued focus on meeting the rigorous requirements of global regulatory authorities.

Completion Of Russian GMP Inspection

- Successful completion of the Russian GMP inspection at API facility at Dholka.

Completion of NAFDAC Inspection

- Successful completion of the National Agency for Food and Drug Administration Nigeria inspection at our Oral Solid Dosage (OSD) Unit-2, facility at Valthera.

Completion of EU GMP Inspection

- Successful completion of the European Union Good Manufacturing Practice inspection at our manufacturing facility located at Limbasi. This milestone marks a significant achievement for Concord, as a successful EU-GMP inspection not only validates our commitment to global quality standards but also paves the way for expanding our footprint into new international markets

Key Developments – H1FY26

Discussion with Innovators

- Advanced stage discussion with Innovator companies for generic API supplies & possible conclusion in near future

Second Source Opportunity

- Increase in multiple second source qualification initiatives for our products

Uptick in Injectables revenues

- Acceptability & steady uptick in our Injectables revenues with better visibility for future growth

Pipeline products

- Two products in pipeline expected to be commercialized in next 6 months

Entering Cell & Gene Therapy

- Invested in Cellimmune Biotech Limited. Company is working on new ways to treat cancer using the body's own immune system. Developing advanced therapies like CAR-T cells, which are specifically designed to find and destroy cancer cells

Q2 & H1FY26 Key Highlights

	Challenges	Mitigation
Delay in renewal of Written Confirmation from CDSCO to supply in European Union	The renewal application for the Written Confirmation from the Central Drugs Standard Control Organization (CDSCO), New Delhi — a **requirement for selling products** in the European region — was submitted in July but experienced delays, which impacted our sales in the European Union.	We have now received the requisite **approval on 4th November**, and we expect to **recover sales momentum in the current quarter**
Shift in procurement patterns from US Customers	Due to **uncertainties on the tariff situations** and global trade war, we experienced delay in the second source opportunities & delay in procurement patterns of the customers from the US	After receiving clarification in September that tariffs do not apply to generic products, **we observed an increase in order flow & positive moment in second source opportunity**
Government tender on Hold in Middle East	A tender-based contract for the Middle East region, supplied through the Indian entity, was put on hold due to the ongoing uncertainties/conflict/war situation in the region, resulting in an impact on revenue	The tendering process has not yet been initiated; however, we remain **optimistic of resuming our supplies**

The challenges resulted in the **postponement of sales** to subsequent quarters; however, **there has been no loss in business opportunity**

Despite subdued revenue impacting overall profitability

Unit economics (Gross Profit/EBIDTA) on an improving trend

Q2 & H1FY26 Consolidated Financial Highlights













Revenue impacted on account of

- Delay in renewal of Written Confirmation from CDSCO to supply in European Union
- Delay in Supplies to US due to uncertainty on tariff situation
- One tender based revenue in Middle East on hold

EBITDA impacted on account of

- Expenses relating to commercialization of new injectable facility at Valthera in the previous quarter
- EBITDA margin excluding the expenses related to new facilities stands at 41% in line with EBITDA margins for Q2FY25

Q2 & H1FY26 Segment wise Revenue Split

API Revenue (Rs. in Crs)



Formulation Revenue (Rs. in Crs)



Total Revenue (Rs. in Crs)



API : Formulation (Q2FY26)



API : Formulation (H1FY26)



CONCORD BIOTECH
Biotech for Mankind...

Q2 & H1FY26 Geography wise Revenue Split

Domestic Revenue (Rs. in Crs)



Exports Revenue (Rs. in Crs)



Total Revenue (Rs. in Crs)



Domestic : Export (Q2FY26)

Domestic : Export (H1FY26)

CONCORD BIOTECH
Biotech for Mankind...

Management Commentary

Ankur Vaid

Joint Managing Director &
Chief Executive Officer

Commenting on the Q2 & H1FY26 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said,

Revenue for Q2 declined due to the postponement of sales caused by delays in receiving written renewal confirmation from CDSCO, New Delhi; order holds from U.S. customers amid trade wars and uncertainties; and the deferment of supplies under a government contract in the Middle East affected by conflicts. We see this as a timing difference and the sales will be recouped in the subsequent quarters.

Our gross margins for the quarter remained robust, expanding by 480 basis points year-over-year in Q2 FY26. EBITDA margin stood at 36%, primarily impacted by expenses associated with the commercialization of our new injectable facility commissioned in March 2025, for which revenues are now building up. Excluding the impact of these new facility-related expenses, EBITDA margin stood at 41%. Despite a temporary dip in revenues, we have successfully maintained profitability and stability at the unit economics level.

On the positive side, we have been able to secure multiple regulatory approvals for our manufacturing sites ensuring consistent supplies and deeper penetration into the global markets. We are also now in advance stages of discussions with leading Innovator companies for API supplies and are optimistic about concluding these engagements in the near future. Alongside, we are also witnessing increasing traction in second source qualification initiatives, reflecting growing trust in our products and capabilities.

Going forward, by expanding geographically, deepening client relationships, and broadening our product portfolio—especially through API & formulation products — we are well-positioned to capture future growth. We remain focused on strengthening our domestic and global presence, investing in innovation, and delivering sustainable, long-term value to our stakeholders.

Q2 & H1FY26 Consolidated Profit & Loss Account

Profit and Loss (Rs. in Crs)	Q2FY26	Q2FY25	YoY	Q1FY26	Q-o-Q	H1FY26	H1FY25	YoY
Revenue from Operations	**247**	**310**	**-20%**	**204**	**21%**	**451**	**526**	**-14%**
Cost of Goods Sold	49	76		45		94	125	
Gross Profit	**198**	**234**	**-15%**	**159**	**25%**	**357**	**401**	**-11%**
Gross Profit Margin	**80.2%**	**75.4%**		**77.9%**		**79.1%**	**76.3%**	
Employee Cost	44	34		38		82	65	
Other Expenses	65	64		60		125	118	
EBITDA	**88**	**137**	**-35%**	**61**	**44%**	**150**	**218**	**-31%**
EBITDA Margin	**35.8%**	**44.1%**		**30.1%**		**33.2%**	**41.4%**	
Depreciation	18	13		18		36	26	
Other Income	13	10		14		27	20	
EBIT	**83**	**133**	**-37%**	**57**	**46%**	**141**	**212**	**-34%**
Finance Cost	0	0		0		0	0	
Share in Profit/(loss) in JV and Associates	2	-3		1		4	-2	
Profit before Tax	**86**	**130**	**-34%**	**59**	**46%**	**144**	**210**	**-31%**
Tax	23	35		15		37	55	
PAT	**63**	**96**	**-34%**	**44**	**43%**	**107**	**155**	**-31%**
PAT Margin %	**25.5%**	**30.9%**		**21.6%**		**23.7%**	**29.5%**	

Consolidated Balance Sheet

Assets (in Rs. Crs)	Sept-25	Mar-25
Non - Current Assets	**943.3**	**899.0**
Property Plant & Equipment's	786.6	791.8
CWIP	74.2	50.1
Intangible assets	0.4	0.6
Intangible assets under development	1.2	0.5
Goodwill	0.4	-
Right of use asset	1.4	2.3
Investment accounted for using equity method	4.5	0.7
Financial Assets		
Investments	40.6	18.0
Other Financial Assets	5.3	20.6
Other Non-Current Assets	10.9	12.6
Income Tax Assets (Net)	17.9	1.8
Current Assets	**1,079.8**	**1,135.2**
Inventories	276.3	239.7
Financial Assets		
(i)Investments	312.3	316.5
(ii)Trade receivables	396.8	521.7
(iii)Cash & cash equivalents and Bank Balance	19.0	1.2
Other Financial Assets	50.0	40.8
Other Current Assets	25.4	15.4
Total Assets	**2,023.2**	**2,034.2**

Equity & Liabilities (in Rs. Crs)	Sept-25	Mar-25
Total Equity	**1,826.8**	**1,812.7**
Share Capital	10.5	10.5
Other Equity	1,817.0	1,802.3
Non Controlling Interest	-0.7	-
Non-Current Liabilities	**41.4**	**37.5**
Financial Liabilities		
(i) Lease Liabilities	0.6	0.6
Provisions	2.5	2.8
Deferred Tax Liabilities (Net)	38.4	34.0
Current Liabilities	**155.0**	**184.1**
Financial Liabilities		
(i) Borrowings	-	0.4
(ii) Trade Payables	86.6	113.0
(iii) Lease	1.0	2.0
(iv) Other Financial Liabilities	43.3	41.7
Other Current Liabilities	0.4	11.3
Current tax liabilities (Net)	18.1	10.1
Provisions	5.6	5.5
Total Equity & Liabilities	**2,023.2**	**2,034.2**

Abridged Cashflow Statement

Particulars (in Rs. Crs)	H1FY26	H1FY25
Net Profit Before Tax	**144.42**	**209.86**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	11.67	16.86
Operating profit before working capital changes	**156.09**	**226.72**
Changes in working capital	-56.88	18.20
Cash generated from Operations	**212.97**	**208.52**
Direct taxes paid (net of refund)	61.89	57.46
Net Cash from Operating Activities	**151.08**	**151.06**
Net Cash from Investing Activities	-21.28	-59.68
Net Cash from Financing Activities	-113.42	-99.12
Net Decrease in Cash and Cash equivalents	16.38	-7.74
Add: Cash & Cash equivalents at the beginning of the period	0.90	15.14
Cash & Cash equivalents at the end of the period	17.28	7.40

Formulation Facility
Valthera, Ahmedabad, India

API Facility
Dholka, Ahmedabad, India

API Facility
Limbasi, Ahmedabad, India

Company Overview

Concord Biotech at a Glance

Concord Biotech Limited is a R&D driven biopharma Company that manufactures
Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Key Highlights

Portfolio spanning
30+
Fermentation APIs

138+
Drug Master Files (DMFs) filed globally

100+
Approved formulation products across markets

Fermentation capacity of
1,250m³

5
ANDAs approved for products from our facilities

Overall formulation manufacturing capacity of
802Mn Units

Expertise in Fermentation Technology

- ✓ **Expertise in fermentation**-based API manufacturing with high entry barriers
- ✓ One of the few global players **delivering consistently** in this specialized segment
- ✓ Built one of the **largest fermentation capacities globally**

Continuous Investment in R&D Driven Innovation

- ✓ **Strong focus on R&D** & State-of-the-art R&D facilities.
- ✓ Dedicated **team of scientists**.
- ✓ **Commitment to innovation** enables us to stay ahead of market trends.
- ✓ **Robust pipeline** for addition **of new products** to meet evolving market demands

Upholding the Highest Standards of Quality and Compliance

- ✓ **World-class infrastructure** adhering to global quality benchmark
- ✓ Facilities inspected by **USFDA, EU GMP, WHO, and PMDA, Japan**
- ✓ Presence **in over 70 countries,** including regulated markets

Driven by Expertise and Consistent Performance

- ✓ **Visionary leadership** driving consistent growth and global expansion
- ✓ Evolved from single-product to **multi-product company**
- ✓ Focus on fermentation, research, manufacturing, and compliance
- ✓ Positioned for **sustained leadership through innovation**

Driving Innovation Through Our Expertise

Mission Focus

Dedicated to deliver high-quality product that enhance human health, driven by innovation and customer centricity, fostering partnerships that make a meaningful impact

Visionary Leadership

Led by industry veterans. Our strategic decisions help us navigate challenges and drive sustained growth. This positions us as a trusted industry leader, committed to shaping a healthier tomorrow

Regulatory Compliance

Rigorous adherence to regulatory standards is integral to our operations, ensuring product integrity and customer trust, bolstering our reputation as a reliable partner in healthcare



Fermentation Expertise

Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines

Diversified Portfolio

We offer full baskets of immunosuppressants in addition to our products in oncology and anti infectives making total count of 30 fermentation-based API's. This helps in ensuring resilience against market fluctuations and meeting diverse pharmaceutical needs effectively

Commitment to Innovation

Our heavy investment in R&D drives continuous process optimization, new product development, and industry leadership, fueling breakthroughs that shape the future of healthcare

API Business Overview

API Overview

One of the **leading global** developers and manufacturers of **Fermentation-based APIs**

Focus on **Niche Fermentation API's** with **backward integration** to Key Starting Material

Diversified Product Portfolio of API's including **Immuno-suppressant, Oncology, Anti-Infectives & Anti-Fungal**

Key Products

Immunosuppressant

- Tacrolimus
- Mycophenolate Mofetil
- Mycophenolate Sodium
- Cyclosporine
- Sirolimus
- Pimecrolimus
- Everolimus Premix 2%
- Voclosporin

Oncology

- Temsirolimus
- Everolimus
- Romidepsin
- Mitomycin
- Dactinomycin
- Staurosporin
- Midostaurne
- Everolimus Premix 9.09%

Antibacterial

- Mupirocin
- Mupirocin Calcium
- Polymyxin B Sulfate
- Teicoplanin
- Vancomycin Hydrochloride
- Fidaxomicin

Antifungal

- Anidulafungin
- Capspofungin Acetate
- Micafungin Sodium
- Amphotericin B
- Nystatin

Others

- Lovastatin
- Pravastatin Sodium
- Enzymes

FY25 – **Rs~ 940** Crores Revenue

FY25 – **78%** Revenue Split

30+ Fermentation APIs

Formulation Business Overview

Formulation Overview

Commercialization of Formulations business in 2016 to capitalize on the **benefits of backward integration**

Operate through **B2B model** across regulated and emerging markets
For India Market, operate via **B2B & B2C model**

Oral Solid Dosages (tablets, capsules and oral suspension)
Injectables (Liquid Vials, Dry Powder Filling, Sterile Lyophilized APL)

Key Products

Antifungal

CRITICAL CARE
- Amfoterol™
- Anicord™
- Caspocon™
- Micacord™
- Vorixia™
- Picocord GR™

NEPHROLOGY
- Conimab
- Gammacord

Antibiotics

CRITICAL CARE
- Dapute ™
- Fosutrac ™
- Pobix ™
- Teicocord ™
- Vanogard ™
- Cricolist ™
- Mepecon ™
- Mepecon
- Minocrit ™
- Tigicon ™
- Primataz ™
- Muprevent ™

Plasma Products

CRITICAL CARE
- Gamacon ™
- Obulin ™

RHEUMATOLOGY
- Conimab
- Gammacord

Transplant & Immuno

NEPHROLOGY
- Tacrocord
- Mofecon
- Evercon
- Conimune ME
- Cyclograf
- Valocon
- Conimab

Chronic Kidney Disease

NEPHROLOGY
- Darbecon
- Epocord
- Sevecord
- Coniron
- Cinacet
- Valolog
- Upshield
- Milipro
- Nabosis
- Kalcord
- Picatol
- Kanilev

Immunology

RHEUMATOLOGY
- Adacord
- Arthimide 1
- Arthimide 2
- Conimba 1
- Conimba 2
- Conimmune 25
- Cyclograp
- Mofecon 250
- Tacrocord 0.25
- Tofajoint ER
- Tofajoint
- Unuric 40

FY25 – **Rs ~ 260** Crores Revenue

FY25 – **22%** Revenue Split

100+ Approved Products

Trusted CDMO partner for Fermentation & Semi-Synthetic API's

CDMO Overview

Provide **contract research and manufacturing services** for developing APIs and formulations.

Prioritizes innovation, **backed by a DSIR-certified R&D facility** with a team of 180+ people

Expertise in fermentation technology and **strong R&D infrastructure** enable us to undertake complex projects and deliver **high-quality outcomes**

Key Strengths & Opportunities

- **Advanced fermentation capabilities**, expertise in strain isolation and enhancement, and scalable processes
- Facilitates **smooth transitions from lab research to full-scale production**
- **Specializes in Contract Research & Manufacturing,** with a focus on fermentation and semi-synthesis
- **Ample capacities** with necessary regulatory approvals **to ensure smooth & consistent supply**

Services Include

- ❖ **Strain Improvement**
- ❖ **Media Optimization**
- ❖ **Process Development**
- ❖ **Downstream Processing**

Pushing Boundaries through Manufacturing Capabilities

Unit I (API) – Dholka, Gujarat

FY2000 Operations commenced

112302 sq.m. Spread across

450 m^3 Installed capacity

Unit II (Formulations) – Valthera, Gujarat

FY2016 Operations commenced

94826 sq.m. Spread across

802Mn Units Installed capacity

Unit III (API) – Limbasi, Gujarat

FY2021 Operations commenced

596309 sq.m. Spread across

800 m^3 Installed capacity

Unit IV (Injectables) – Valthera, Gujarat

FY2025 Operations commenced

36,441 sq.m. Spread across

Installed capacity of **13Mn** Liquid Vials, **12Mn** Dry Power Filling & **2200** Kgs Sterile Lyophilized APL

CONCORD BIOTECH
Biotech for Mankind...

Pioneering R&D Capabilities

180

R&D Employee Strength

7/5

Approved ANDA/ Finished Products

> 135

API DMFs

22+

Non-Infringing Processes



Robust pipeline of **more than 10 products** across different therapeutic segments of Oncology, Anti-Infectives & Anti-Fungal

R&D Initiatives:

- Cost Improvement
- New Product Development
- Process Improvement
- Technology Transfer
- Scale-Up Initiatives
- Enhancement of Backward Integration

State-of-the-Art Facilities: Where Ideas Materialise

API R&D Lab

- Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as well as strain improvement processes.
- Our R&D strengths enable us to drive innovation and develop new active pharmaceutical ingredients efficiently
- Equipped with fermenters and a pilot plant facility, allowing us to seamlessly scale up fermentation processes from lab scale to commercial production scale.

Our integrated R&D capabilities across API and formulations development allow us to bring new and innovative pharmaceutical products to the market effectively.

Formulations R&D Lab

- Focus on formulation development leveraging advanced analytical capabilities.
- R&D team works closely with our API experts to ensure our products meet the highest standards of quality and efficacy while providing optimal drug delivery and patient convenience

DMF Fillings Across Geographies

	Molecules	US	EU	Canada	Japan	China
Immuno-Suppressants	Tacrolimus	✓	✓	✓	✓	✓
	Mycophenolate Mofetil	✓	✓	✓	✓	✓
	Mycophenolate Sodium	✓	✓	✓		✓
	Cyclosporine	✓	✓	✓	✓	✓
	Sirolimus	✓	✓	✓	✓	
	Pimecrolimus	✓				
	Voclosporin	✓				
Oncology	Temsirolimus	✓	✓			
	Everolimus	✓	✓	✓	✓	
	Romidepsin	✓				✓
	Mitomycin	✓	✓	✓		
	Dactinomycin	✓				
	Midostaurin	✓				
Anti-Bacterial	Mupirocin	✓	✓	✓		✓
	Nystatin	✓	✓			
	Mupirocin Calcium	✓	✓	✓		
	Vancomycin Hydrochloride	✓	✓			
Others	Lovastatin	✓	✓			
	Pravastatin Sodium	✓	✓			

Wide Range of Formulation Product Portfolio for Overseas Markets

Regulated Markets

Product Name	ANDA Approval
Mycophenolate Mofetil Capsules	✓
Mycophenolic Acid DR Tablets USP	✓
Mycophenolate Mofetil Tablets	✓
Tacrolimus Capsules USP	✓
Teriflunomide Tablets	✓

Emerging Markets

Product Name
Mycophenolate Mofetil Capsules
Mycophenolate Mofetil Tablets
Mycophenolate Mofetil Suspension
Mycophenolate Sodium 180mg Tablets
Mycophenolate Sodium 360mg Tablets
Tacrolimus 0.5mg Capsules
Tacrolimus 1mg Capsules
Tacrolimus 5mg Capsules

Diversified Customer Base

70+ Countries

250+ Customers

Worldwide Presence

Tailored Distribution Models

Collaborative Partnerships

New Customer Addition / Product Addition in Existing Customers



Reducing Customer Concentration % Contribution from Top 10 Customers



CONCORD BIOTECH
Biotech for Mankind...

Paving the Way for Sustainability

Our Vision for Sustainability

- Sustainable Manufacturing
- Global Green Leadership
- Environmental Conservation

The Path of Sustainability

- Research & Development
- Efficient Resource Management
- Constant Improvement & Adaptation

Awarded Bronze Medal by EcoVadis

Our Initiatives on Sustainability

- ✓ Corporate Social Responsibility
- ✓ Driving towards sustainable future
- ✓ Reduced ecological harm
- ✓ Improved water quality

Received

ISO-14001:2015 & ISO-45001:2018

Certifications

CONCORD BIOTECH
Biotech for Mankind...

Key Business Differentiators

End-to-End Expertise in Complex Fermentation Value Chain

Leadership Position

Leadership position for select molecules in global markets

1250 M^3

Fermentation Capacity across two API facilities

01

Over 2 Decades

Experience in the industry with a demonstrated track record of developing niche and complex molecules

02

03

30+ Fermented based API's

One of leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants oncology and Anti-infectives in terms of market share

04

Overview of Integrated Platform

- R&D
- Patents
- Key Starting Material
- API Manufacturing
- Formulations
- Marketing & Distribution

Constructing Formidable Barriers to Entry

Significant Entry Barriers

- Complex Process & Technical Expertise
- Capital Intensive Infrastructural Requirements
- Operational Requirements (large scale fermenters)
- Long gestation Period

Complex technical capabilities, difficulties in scaling up operations and substantial capital investment required have resulted in **significant barriers to entry** in the fermentation-based API space

Concord Biotech's Strong Capabilities

01 Portfolio Across a **Wide Range of Therapeutic Areas**

02 **Scaled manufacturing facilities** with a consistent **regulatory compliance** track record

03 **Flexible** plant configuration

04 **Backward Integrated** to KSM level

05 **Regulatory Approvals** for global markets

06 **Commercialized** a wide spectrum of fermentation-based APIs

Key Growth Drivers



API Business

- Expanding API Portfolio
- Marketing existing APIs to new customers
- Increasing wallet share with existing customers

Formulations Business

- Expanding portfolio through own development & in-licensing
- Launching new dosage forms including injectables
- Expanding geographic reach in India, EMs and the US

CDMO Business

- Leverage established fermentation platform, strong R&D, manufacturing and relationships with global players
- Trusted CDMO partner for Fermentation & Semi-Synthetic API's

Operational Efficiencies

- Utilization & Capex to drive future growth
- Focus on process efficiency, operating leverage and product mix

For further Information, please contact

Company:

CONCORD BIOTECH

Concord Biotech Limited

CIN: L24230GJ1984PLC007440
Mr. Lalit Sethi – Chief Financial Officer
lalitsethi@concordbiotech.com

www.concordbiotech.com

Investor Relations Advisor:

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285
Mr. Sagar Shroff / Mr. Vatsal Shah
sagar.shroff@sgapl.net / vatsal.shah@sgapl.net
+91 98205 19303 / +91 88796 59884
www.sgapl.net